drugset / Trial / NCT02042729

A Phase 1 Comparative Study of E2022 Current and New Patch Formulations

NCT02042729

Phase 1 Completed 34 enrolled Eisai Inc.
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and pharmacokinetics of new patch formulation (tape) of E2022 by conducting patch test.

Timeline

Start
2012-08
Primary completion
2012-10
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule Topical

Indications

No indication recorded.